25 November 2014 in Birth Defects Research Part C: Embryo Today: Reviews
1 February 2017 in International braz j urol
LRLuíza de Oliveira Rodrigues
Luíza de Oliveira Rodrigues
DADaniela Castelo Azevedo
LCLélia Maria de Almeida Carvalho
Lélia Maria de Almeida Carvalho
SKSilvana Márcia Bruschi Kelles
Silvana Márcia Bruschi Kelles
+3
This study aimed to retrospectively evaluate a cohort of patients with prostate cancer and persistent urinary incontinence after radical prostatectomy. From January 2004 to December 2015, eighty-six individuals were identified to have received an AUS implant, provided by a private nonprofit HMO operating in Belo Horizonte, Brazil. On total, there were 91 AUS implants, with a median interval between radical prostatectomy and AUS implant of 3.6 years (IQR 1.9 to 5.5). The rate of AUS cumulative survival, after a median follow-up of 4.1 years (IQR 1.7-7.2 years), was 44% (n=40). The median survival of AUS implants was 2.9 years (IQR 0.5-7.9 years). Thirty-seven AUS implants (40.7%) resulted in grade III surgical complications. There were 5 deaths at 2.1, 4.7, 5.7, 5.7 and 6.5 years of follow-up, but none due to causes directly associated to the AUS implant. Persistent severe incontinence was documented in 14 (15.3%) additional patients. From the 51 AUS implants which resulted in grade III surgical complications or persistent severe incontinence, 24 (47.1%) underwent surgical revisions. Explantation of the sphincter or its components was observed in 6 cases (25.0%). Mechanical failure, described as fluid loss and/or inability to recycle the AUS device, was observed in 4 devices (16.7%). In conclusion, although AUS implants are recommended as the gold-standard treatment of severe urinary incontinence after prostatectomy, the observed high rates of malfunction and grade III adverse events are a matter of concern warranting further assessment on the safety and efficacy of these devices.
19 February 2025 in Kidney International
4 July 2014 in Nephrology
LBLuciana Bastos‐Rodrigues
+3
22 November 2019 in BMJ Evidence-Based Medicine
At the 2019 EBMLive conference (see box 1), we wanted to better understand the problems and challenges that EMCRs encounter. In particular, we focused on EMCRs in those LMICs undergoing major health system transformations, such as Brazil and India. We asked the six recipients of the Building Capacity Bursaries (all co-authors of this commentary) to describe the challenges that they have encountered individually and among their peers, along with potential solutions (see box 2). Their responses reflect healthcare professionals who practice in South America, Africa, the Middle East and Asia. While some challenges are specific to certain settings, we tried to identify, highlight and describe broad overarching themes.
7 January 2012 in Pediatric Nephrology
MPMaria Goretti M. G. Penido
Maria Goretti M. G. Penido
+1